17284 destruction mal ls f/e/e/n/l/m3.1-4
Also known as: destroy malignant 3.1-4.0 face
Destruction of malignant skin lesion (face, ears, eyelids, nose, lips, mucous membrane) with largest diameter between 3.1 and 4.0 centimeters.
In Plain Language
Large facial skin cancer
Clinical Context
Used for larger facial malignancies measuring 3.1-4.0 cm. Often requires reconstruction with local or regional flaps.
RVU Breakdown
| Work RVU | 3.12 |
| Total RVU | 3.12 |
Est. Medicare Payment
National estimate based on 2026 CMS PFS Conversion Factor ($33.40). Actual payment varies by locality (GPCI adjustment).
Billing & Documentation
As a surgical CPT code, proper documentation must include the operative report detailing the procedure performed, patient positioning, approach, findings, and any complications. This code has a 10-day global period — follow-up visits within 10 days of the procedure are included in the reimbursement. Ensure the diagnosis code (ICD-10) supports medical necessity for the procedure.
How This Code Compares
With a work RVU of 3.12, this code ranks in the 22nd percentile among Surgery codes — 2.6x below the median (8.00). The highest wRVU in this category is 106.19.
Specialties
Frequently Asked Questions
What is CPT code 17284?
CPT 17284 (destruction mal ls f/e/e/n/l/m3.1-4) is a Surgery code. Destruction of malignant skin lesion (face, ears, eyelids, nose, lips, mucous membrane) with largest diameter between 3.1 and 4.0 centimeters.
What is the wRVU value for CPT 17284?
The work RVU for CPT 17284 is 3.12. This code is primarily used by Dermatology, Surgical Oncology, Facial Surgery. It has a 10-day global period.
When is CPT 17284 used?
Used for larger facial malignancies measuring 3.1-4.0 cm. Often requires reconstruction with local or regional flaps.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.